Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

134P - Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory advanced NSCLC patients: a prospective, single arm, two stage study

Date

08 Dec 2022

Session

Poster Display

Presenters

Baohui Han

Citation

Annals of Oncology (2022) 16 (suppl_1): 100104-100104. 10.1016/iotech/iotech100104

Authors

B. Han1, B. Zhang2, H. Zhong2, C. SHI3, Z. Gao3, R. Zhong2, A. Gu3, T. Chu2, H. Wang3, L. Xiong3, W. Zhang3, X. Zhang2, B. YAN3, J. Teng3, W. Wang3, H. Bai3, R. Qiao3, L. Cheng3, Y. Kuang3

Author affiliations

  • 1 Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai/CN
  • 2 Shanghai Chest Hospital, Shanghai Jiao Tong University, 200030 - Shanghai/CN
  • 3 Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 134P

Background

Vascular endothelial growth factor (VEGF) inhibition may reverse suppressive microenvironment and recover sensitivity to subsequent immune checkpoint inhibitors (ICIs).

Methods

This is a phase Ib/IIa, single-arm study, comprising dose finding (Part A) and expansion cohort (Part B). Immune checkpoint-inhibitor refractory NSCLC were enrolled. The first 21-day treatment cycle was a safety observation period (phase Ib) followed by a phase II expansion cohort (nivolumab 360mg, every 3 weeks, plus anlotinib, RP2D, 14 days on and 7 days off). The primary objective is recommended phase 2 dose (RP2D, part A) safety (part B) and ORR (part B), respectively.

Results

Between November 2020 and March 2022, 35 patients were screened and 21 eligible patients were enrolled (6 patients in Part A). The PR2D is anlotinib 12 mg/day orally (14 days on and 7 days off) and nivolumab (360mg every 3 weeks). Adverse events of any cause and treatment-related were reported in all patients. Two patients (9.5%) experience grade 3 TRAE. No grade 4 or higher adverse events were observed. Serious adverse were reported in 4 patients. There were 6 and 4 patients experience anlotinib and nivolumab disruption due to TRAE. Dese reduction to 10mg at any time was required in 5 patients and no patients decreased to 8mg. ORR and DCR was 19.0% and DCR is 76.2%, respectively. Median PFS and OS were PFS was 7.43 months (95% CI, 4.54-10.21m) and 19.1months (95% CI, 10.37-NE).

Conclusions

Our study suggested that full dose anlotinib combined with nivolumab showed positive safety and efficacy signal. Further study is warranted.

Clinical trial identification

NCT04507906.

Legal entity responsible for the study

Baohui Han.

Funding

This work was supported by Shanghai Committee of Science and Technology (Project No. 21Y11913800), National Natural Science Foundation of China (Project No.82072573). Study drugs were provided by Bristol Myers Squibb and Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.